Trillium Asset Management LLC Sells 1,528 Shares of Penumbra, Inc. (NYSE:PEN)

Trillium Asset Management LLC lowered its position in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 3.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 37,547 shares of the company's stock after selling 1,528 shares during the period. Trillium Asset Management LLC owned about 0.10% of Penumbra worth $8,916,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of PEN. Janus Henderson Group PLC grew its position in Penumbra by 128.1% during the 3rd quarter. Janus Henderson Group PLC now owns 668,873 shares of the company's stock worth $129,967,000 after acquiring an additional 375,684 shares during the last quarter. Champlain Investment Partners LLC lifted its holdings in Penumbra by 20.6% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,547,972 shares of the company's stock worth $300,786,000 after buying an additional 264,122 shares during the period. Massachusetts Financial Services Co. MA acquired a new position in Penumbra during the 3rd quarter worth about $31,965,000. Braidwell LP lifted its holdings in Penumbra by 70.0% during the 3rd quarter. Braidwell LP now owns 361,428 shares of the company's stock worth $70,229,000 after buying an additional 148,834 shares during the period. Finally, Baillie Gifford & Co. lifted its holdings in Penumbra by 23.4% during the 4th quarter. Baillie Gifford & Co. now owns 730,233 shares of the company's stock worth $173,416,000 after buying an additional 138,387 shares during the period. Institutional investors own 88.88% of the company's stock.

Penumbra Stock Down 0.1 %

Penumbra stock traded down $0.40 during midday trading on Friday, reaching $280.93. The stock had a trading volume of 737,365 shares, compared to its average volume of 397,643. Penumbra, Inc. has a 12 month low of $148.00 and a 12 month high of $310.00. The company has a market capitalization of $10.82 billion, a P/E ratio of 826.25, a PEG ratio of 2.83 and a beta of 0.51. The company has a fifty day moving average price of $272.70 and a two-hundred day moving average price of $240.30. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02.

Remove Ads

Penumbra (NYSE:PEN - Get Free Report) last issued its earnings results on Tuesday, February 18th. The company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.09. The business had revenue of $315.52 million during the quarter, compared to analyst estimates of $311.63 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. As a group, equities analysts expect that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PEN has been the topic of several recent research reports. JPMorgan Chase & Co. lifted their target price on Penumbra from $230.00 to $285.00 and gave the stock an "overweight" rating in a report on Wednesday, February 19th. StockNews.com downgraded Penumbra from a "buy" rating to a "hold" rating in a report on Friday, February 28th. Citigroup lifted their target price on Penumbra from $220.00 to $245.00 and gave the stock a "neutral" rating in a report on Wednesday, December 11th. Canaccord Genuity Group lifted their target price on Penumbra from $323.00 to $340.00 and gave the stock a "buy" rating in a report on Wednesday, February 19th. Finally, Robert W. Baird boosted their price objective on Penumbra from $305.00 to $328.00 and gave the company an "outperform" rating in a research note on Wednesday, February 19th. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $294.47.

Insiders Place Their Bets

In related news, EVP Johanna Roberts sold 600 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $287.43, for a total transaction of $172,458.00. Following the completion of the sale, the executive vice president now directly owns 66,539 shares of the company's stock, valued at approximately $19,125,304.77. This trade represents a 0.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Harpreet Grewal sold 167 shares of the stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $241.28, for a total value of $40,293.76. Following the sale, the director now directly owns 8,530 shares of the company's stock, valued at $2,058,118.40. The trade was a 1.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 81,518 shares of company stock valued at $22,994,979. Corporate insiders own 5.00% of the company's stock.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.